{"id":993,"date":"1998-12-01T12:07:00","date_gmt":"1998-12-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/angioneurotisches-oedem-als-nebenwirkung-von-losartan"},"modified":"1998-12-01T12:07:00","modified_gmt":"1998-12-01T11:07:00","slug":"angioneurotisches-oedem-als-nebenwirkung-von-losartan","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/angioneurotisches-oedem-als-nebenwirkung-von-losartan","title":{"rendered":"Angioneurotisches \u00d6dem als Nebenwirkung von Losartan"},"content":{"rendered":"<p>Das angioneurotische \u00d6dem ist eine relativ seltene Nebenwirkung der Therapie mit ACE-Hemmern (s.a. AMB 1992, 26, 95; 1993, 27, 77; 1994, 28, 25). Man hat dieses Ph\u00e4nomen bisher damit erkl\u00e4rt, da\u00df ACE-Hemmer nicht nur die Bildung von Angiotensin II hemmen, sondern auch den Abbau des Vasodilatators Bradykinin, der in der Pathogenese dieses \u00d6dems eine Rolle [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das angioneurotische \u00d6dem ist eine relativ seltene Nebenwirkung der Therapie mit ACE-Hemmern (s.a. AMB 1992, 26, 95; 1993, 27, 77; 1994, 28, 25). Man hat dieses Ph\u00e4nomen bisher damit erkl\u00e4rt, da\u00df ACE-Hemmer nicht nur die Bildung von Angiotensin II hemmen, sondern auch den Abbau des Vasodilatators Bradykinin, der in der Pathogenese dieses \u00d6dems eine Rolle [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1733,1732,316,309,312,314,313,315,317,320,311,307,319,310,1226,1636,1228,321,2503,306,366],"class_list":["post-993","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angioneurotisches-oedem","tag-angiooedem","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-candesartan","tag-eprosartan","tag-irbesartan","tag-losartan","tag-quincke-oedem","tag-sartane","tag-valsartan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=993"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/993\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}